At least three non-hallucinogenic structural ibogaine analogues will enter preclinical development within 36 months, driven by neuroplasticity mechanism findings

Researchers will start developing versions of ibogaine that don't make you hallucinate but keep the healing effects by targeting brain plasticity. Companies will invest in these because they're easier to regulate and market.

BDNF/TrkB-mediated juvenile-like plasticity induction is a well-characterized drug discovery target that reliably attracts medicinal chemistry investment. Visual cortex plasticity data provides a quantifiable preclinical endpoint. However, 'preclinical development' must mean documented IND-enabling studies or published preclinical data, not internal pipeline announcements. 36-month window from May 2026 is plausible given existing ibogaine analogue programs (e.g., tabernanthalog derivatives) already underway.